A combination of AstraZeneca PLC's PD-L1 inhibitor Imfinzi and its much-maligned investigational CTLA-4 inhibitor tremelimumab has sprung a very pleasant surprise by improving survival rates in liver cancer patients.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?